Initial dosage optimization of ciclosporin in pediatric Chinese patients who underwent bone marrow transplants based on population pharmacokinetics

Bone marrow transplants (BMT) are an established therapeutic strategy for patients with severe aplastic anemia, acute lymphoblastic leukemia, acute myeloid leukemia or chronic myeloid leukemia. However, the successful application of BMT is limited by graft-vs.-host disease (GVHD). Ciclosporin has been widely used for treating GVHD in pediatric patients who underwent BMT. The present study aimed to optimize the dosage of ciclosporin for safety and effectiveness based on population pharmacokinetics. A non-linear mixed-effects model was used to analyze the clinical data of pediatric patients who underwent BMT between September 2016 and September 2019 at the Children's Hospital of Fudan University. Monte Carlo simulations were used to identify the optimal dose of ciclosporin. The final population pharmacokinetic model indicated that body weight and days post-transplant influenced the clearance of ciclosporin in pediatric patients who underwent BMT. The present study indicated that the optimal initial dose of ciclosporin for pediatric patients weighing 5-30 kg who underwent BMT was 6 mg/kg/day split into 2 doses.

[1]  Hong Xu,et al.  Population pharmacokinetics and initial dosing regimen optimization of cyclosporin in pediatric hemophagocytic lymphohistiocytosis patients , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[2]  Q. Zheng,et al.  Model extrapolation to a real-world dataset: evaluation of tacrolimus population pharmacokinetics and drug interaction in pediatric liver transplantation patients , 2020, Xenobiotica; the fate of foreign compounds in biological systems.

[3]  Dong-Dong Wang,et al.  Wuzhi capsule and haemoglobin influence tacrolimus elimination in paediatric kidney transplantation patients in a population pharmacokinetics analysis: A retrospective study , 2019, Journal of clinical pharmacy and therapeutics.

[4]  Chunfu Wu,et al.  Population pharmacokinetics of cyclosporine in Chinese children receiving hematopoietic stem cell transplantation , 2019, Acta Pharmacologica Sinica.

[5]  F. Zhou,et al.  Population pharmacokinetics of cyclosporine A in Chinese patients with nephrotic syndrome in individualized drug administration
. , 2019, International journal of clinical pharmacology and therapeutics.

[6]  W. Winkelmayer,et al.  A non-randomized trial of conversion from ciclosporin and tacrolimus to tacrolimus MR4 in stable long-term kidney transplant recipients: Graft function and influences of ABCB1 genotypes , 2019, PloS one.

[7]  Xia Zhao,et al.  Population pharmacokinetics and dose simulation of oxcarbazepine in Chinese paediatric patients with epilepsy , 2019, Journal of clinical pharmacy and therapeutics.

[8]  Jie Ding,et al.  Population pharmacokinetics and dosage optimization of tacrolimus in pediatric patients with nephrotic syndrome
. , 2019, International journal of clinical pharmacology and therapeutics.

[9]  Dongdong Wang,et al.  Cyclosporin population pharmacokinetics in pediatric refractory nephrotic syndrome based on real-world studies: Effects of body weight and spirolactone administration , 2019, Experimental and therapeutic medicine.

[10]  Limei Zhao,et al.  Dosage Optimization Based on Population Pharmacokinetic Analysis of Tacrolimus in Chinese Patients with Nephrotic Syndrome , 2019, Pharmaceutical Research.

[11]  Xu Meng,et al.  Optimal sampling time-point for cyclosporin A concentration monitoring in heart transplant recipients. , 2018, Experimental and therapeutic medicine.

[12]  Yi Zheng,et al.  Population pharmacokinetics of tacrolimus in children with nephrotic syndrome , 2018, British journal of clinical pharmacology.

[13]  Bao-Ping Xu,et al.  Population Pharmacokinetics and Dosing Optimization of Azithromycin in Children with Community-Acquired Pneumonia , 2018, Antimicrobial Agents and Chemotherapy.

[14]  Dan Wu,et al.  Population pharmacokinetics of vancomycin and AUC-guided dosing in Chinese neonates and young infants , 2018, European Journal of Clinical Pharmacology.

[15]  I. Odeyemi,et al.  Systematic Review and Meta-Analysis of Tacrolimus versus Ciclosporin as Primary Immunosuppression After Liver Transplant , 2016, PloS one.

[16]  I. Odeyemi,et al.  A cost-utility analysis of prolonged-release tacrolimus relative to immediate-release tacrolimus and ciclosporin in liver transplant recipients in the UK , 2016, Journal of medical economics.

[17]  D. Steinbach,et al.  Superior outcome using cyclosporin A alone versus cyclosporin A plus methotrexate for post-transplant immunosuppression in children with acute leukemia undergoing sibling hematopoietic stem cell transplantation , 2015, Journal of Cancer Research and Clinical Oncology.

[18]  C. Gluud,et al.  Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. , 2013, The Cochrane database of systematic reviews.

[19]  S. Zeng,et al.  Population pharmacokinetics of ciclosporin in Chinese children with aplastic anemia: effects of weight, renal function and stanozolol administration , 2013, Acta Pharmacologica Sinica.

[20]  A. Åsberg,et al.  Endomyocardial, intralymphocyte, and whole blood concentrations of ciclosporin A in heart transplant recipients , 2013, Transplantation research.

[21]  M. Moritz,et al.  Ciclosporin Use During Pregnancy , 2013, Drug Safety.

[22]  Q. Zheng,et al.  Pharmacometrics: a quantitative tool of pharmacological research , 2012, Acta Pharmacologica Sinica.

[23]  J. Janssen,et al.  Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy. , 2012, British journal of clinical pharmacology.

[24]  A. Sturm,et al.  Current treatment of ulcerative colitis. , 2011, World journal of gastroenterology.

[25]  N. Holford,et al.  Tips and traps analyzing pediatric PK data , 2011, Paediatric anaesthesia.

[26]  A. Katsarou,et al.  Treatment of autoimmune urticaria with low-dose cyclosporin A: A one-year follow-up. , 2011, Acta dermato-venereologica.

[27]  Yves Bertrand,et al.  Links Between Cyclosporin Exposure in Tissues and Graft-Versus-Host Disease in Pediatric Bone Marrow Transplantation: Analysis by a PBPK Model , 2010, Pharmaceutical Research.

[28]  Z. Hrnčíř,et al.  Cyclosporine A or intravenous cyclophosphamide for lupus nephritis: the Cyclofa-Lune study , 2010, Lupus.

[29]  A. Gottlieb,et al.  Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. , 2010, Journal of the American Academy of Dermatology.

[30]  S. Cremers,et al.  Ciclosporin kinetics in children after stem cell transplantation. , 2008, British journal of clinical pharmacology.

[31]  N. Holford,et al.  Mechanism-based concepts of size and maturity in pharmacokinetics. , 2008, Annual review of pharmacology and toxicology.

[32]  M O Karlsson,et al.  Developmental pharmacokinetics of ciclosporin--a population pharmacokinetic study in paediatric renal transplant candidates. , 2007, British journal of clinical pharmacology.

[33]  W. Shlomchik,et al.  Graft-versus-host disease , 2007, Nature Reviews Immunology.

[34]  P. Marquet,et al.  Population Pharmacokinetics and Bayesian Estimator of Cyclosporine in Pediatric Renal Transplant Patients , 2007, Therapeutic drug monitoring.

[35]  F. Locatelli,et al.  The influence of cyclosporin alone, or cyclosporin and methotrexate, on the incidence of mixed haematopoietic chimaerism following allogeneic sibling bone marrow transplantation for severe aplastic anaemia , 2007, Bone Marrow Transplantation.

[36]  S. Ohga,et al.  Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA‐identical siblings , 2006, British journal of haematology.

[37]  K. Matsuo,et al.  Low-dose cyclosporin a with short-term methotrexate for graft-versus-host disease prophylaxis in allogeneic bone marrow transplantation from human leukocyte antigen—identical siblings: a prospective phase ii study in japanese patients , 2006, International journal of hematology.

[38]  Yizhou Zheng,et al.  Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens. , 2006, Experimental hematology.

[39]  H. Koo,et al.  Assessment of converting from intravenous to oral administration of cyclosporin A in pediatric allogeneic hematopoietic stem cell transplant recipients , 2006, Bone Marrow Transplantation.

[40]  M. Schrappe,et al.  The impact of cyclosporin A on acute graft-versus-host disease after allogeneic bone marrow transplantation in children and adolescents with acute lymphoblastic leukemia , 2005, Bone Marrow Transplantation.

[41]  D. Jewell,et al.  Cyclosporine for induction of remission in Crohn's disease. , 2005, The Cochrane database of systematic reviews.

[42]  S. Steinberg,et al.  Clinical "cytokine storm" as revealed by monocyte intracellular flow cytometry: correlation of tumor necrosis factor alpha with severe gut graft-versus-host disease. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[43]  Y. Bertrand,et al.  Relationship between CsA trough blood concentration and severity of acute graft-versus-host disease after paediatric stem cell transplantation from matched-sibling or unrelated donors , 2003, Bone Marrow Transplantation.

[44]  G. Hill,et al.  The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. , 2000, Blood.

[45]  Raiola,et al.  The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation , 2000, British journal of haematology.

[46]  M. Remberger,et al.  Low-dose cyclosporine of short duration increases the risk of mild and moderate GVHD and reduces the risk of relapse in HLA-identical sibling marrow transplant recipients with leukaemia , 1999, Bone Marrow Transplantation.

[47]  W. H. Barr.  Cyclosporine: the case for expanding bioequivalence criteria to include measures of individual bioequivalence in relevant population subsets. , 1999, Transplantation proceedings.

[48]  K. Bradstock,et al.  Antileukemic effects of rapid cyclosporin withdrawal in patients with relapsed chronic myeloid leukemia after allogeneic bone marrow transplantation. , 1998, Leukemia & lymphoma.

[49]  J. Klein,et al.  IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE , 1997, British journal of haematology.

[50]  A. Finlay,et al.  Cyclosporine in severe childhood atopic dermatitis: a multicenter study. , 1996, Journal of the American Academy of Dermatology.

[51]  Nicholas H. G. Holford,et al.  A Size Standard for Pharmacokinetics , 1996, Clinical pharmacokinetics.

[52]  L. Rutzky,et al.  Challenges in Cyclosporine Therapy: The Role of Therapeutic Monitoring by Area Under the Curve Monitoring , 1995, Therapeutic drug monitoring.

[53]  L. Bowers.  Therapeutic monitoring for cyclosporine: difficulties in establishing a therapeutic window. , 1991, Clinical biochemistry.

[54]  R. Storb,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. , 1990, Blood.

[55]  K. Sullivan,et al.  A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. , 1990, Blood.

[56]  T. Hamilton,et al.  Oral cyclosporine for the treatment of alopecia areata. A clinical and immunohistochemical analysis. , 1990, Journal of the American Academy of Dermatology.

[57]  R. Marcus,et al.  Bone marrow transplantation for patients with chronic myeloid leukemia. , 1986, The New England journal of medicine.

[58]  D. Lowenthal,et al.  Critical therapeutic categories: a contraindication to generic substitution? , 1986, Clinical therapeutics.